27273095272978710001555279--12-312021Q1false00000000.100.10272903640.600.224993199P1YP1Y0001555279us-gaap:RedeemableConvertiblePreferredStockMember2020-03-310001555279us-gaap:RedeemableConvertiblePreferredStockMember2019-12-310001555279us-gaap:RedeemableConvertiblePreferredStockMember2020-01-012020-03-310001555279us-gaap:CommonStockMember2021-01-012021-03-310001555279us-gaap:CommonStockMember2020-01-012020-03-310001555279us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember2020-12-222020-12-220001555279us-gaap:CommonStockMemberus-gaap:IPOMember2020-12-222020-12-220001555279us-gaap:RetainedEarningsMember2021-03-310001555279us-gaap:AdditionalPaidInCapitalMember2021-03-310001555279us-gaap:RetainedEarningsMember2020-12-310001555279us-gaap:AdditionalPaidInCapitalMember2020-12-310001555279us-gaap:RetainedEarningsMember2020-03-310001555279us-gaap:AdditionalPaidInCapitalMember2020-03-310001555279us-gaap:RetainedEarningsMember2019-12-310001555279us-gaap:AdditionalPaidInCapitalMember2019-12-310001555279us-gaap:CommonStockMember2021-03-310001555279us-gaap:CommonStockMember2020-12-310001555279us-gaap:CommonStockMember2020-03-310001555279us-gaap:CommonStockMember2019-12-310001555279mass:StockOptionAndIncentivePlan2020Member2021-03-310001555279mass:EmployeeStockPurchasePlan2020Member2021-03-310001555279mass:StockOptionAndIncentivePlan2020Member2020-11-230001555279mass:EmployeeStockPurchasePlan2020Member2020-11-230001555279mass:ProductAndServiceMember2023-04-012021-03-310001555279mass:ProductAndServiceMember2022-04-012021-03-310001555279mass:ProductAndServiceMember2021-04-012021-03-310001555279mass:PharmaceuticalBiotechnologyMembermass:ProductAndServiceMember2021-01-012021-03-310001555279mass:HandheldMembermass:ProductAndServiceMember2021-01-012021-03-310001555279mass:GovernmentAuthorityMembermass:ProductAndServiceMember2021-01-012021-03-310001555279mass:DesktopMembermass:ProductAndServiceMember2021-01-012021-03-310001555279mass:AcademiaMembermass:ProductAndServiceMember2021-01-012021-03-310001555279us-gaap:ServiceMember2021-01-012021-03-310001555279us-gaap:ProductMember2021-01-012021-03-310001555279us-gaap:EMEAMember2021-01-012021-03-310001555279srt:NorthAmericaMember2021-01-012021-03-310001555279srt:AsiaPacificMember2021-01-012021-03-310001555279mass:PharmaceuticalBiotechnologyMembermass:ProductAndServiceMember2020-01-012020-03-310001555279mass:HandheldMembermass:ProductAndServiceMember2020-01-012020-03-310001555279mass:GovernmentAuthorityMembermass:ProductAndServiceMember2020-01-012020-03-310001555279mass:DesktopMembermass:ProductAndServiceMember2020-01-012020-03-310001555279mass:AcademiaMembermass:ProductAndServiceMember2020-01-012020-03-310001555279us-gaap:ServiceMember2020-01-012020-03-310001555279us-gaap:ProductMember2020-01-012020-03-310001555279us-gaap:EMEAMember2020-01-012020-03-310001555279srt:NorthAmericaMember2020-01-012020-03-310001555279srt:AsiaPacificMember2020-01-012020-03-310001555279mass:Revolver2021Member2021-03-012021-03-310001555279us-gaap:IPOMember2020-12-222020-12-220001555279us-gaap:RetainedEarningsMember2021-01-012021-03-3100015552792020-01-012020-12-310001555279us-gaap:RetainedEarningsMember2020-01-012020-03-310001555279mass:Loan2019Member2021-03-112021-03-110001555279mass:Revolver2021Member2021-03-112021-03-110001555279srt:MinimumMembermass:Revolver2021Member2021-03-110001555279srt:MinimumMembermass:Revolver2021Memberus-gaap:PrimeRateMember2021-03-112021-03-110001555279mass:LicenceAndContractMember2020-01-012020-03-310001555279mass:LicenceAndContractMember2021-01-012021-03-310001555279mass:LicenceAndContractMember2021-03-310001555279mass:LicenceAndContractMember2020-12-310001555279mass:ProductAndServiceMember2020-03-310001555279mass:ProductAndServiceMember2019-12-310001555279mass:LicenceAndContractMembersrt:MaximumMember2021-03-310001555279mass:ProductAndServiceMember2021-03-310001555279mass:LicenceAndContractMembersrt:MaximumMember2020-12-310001555279mass:ProductAndServiceMember2020-12-310001555279mass:CustomerTwoMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001555279mass:CustomerTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001555279mass:CustomerOneMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001555279mass:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001555279mass:CustomerTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001555279mass:CustomerThreeMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001555279mass:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001555279mass:CustomerTwoMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001555279mass:CustomerOneMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001555279mass:WarrantsToPurchaseCommonStockMember2021-03-310001555279mass:WarrantsToPurchaseCommonStockMember2020-12-3100015552792019-12-310001555279us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001555279us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001555279us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001555279us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-3100015552792020-03-310001555279us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001555279mass:CommonStockWarrantMember2021-01-012021-03-310001555279us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember2020-01-012020-03-310001555279us-gaap:RedeemableConvertiblePreferredStockMember2020-01-012020-03-310001555279us-gaap:EmployeeStockOptionMember2020-01-012020-03-310001555279us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310001555279us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001555279us-gaap:CostOfSalesMember2021-01-012021-03-310001555279us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-03-310001555279us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-03-310001555279us-gaap:CostOfSalesMember2020-01-012020-03-310001555279us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001555279us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001555279mass:EuropeMiddleEastAndAfricaMemberus-gaap:AccountsReceivableMemberus-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember2021-03-310001555279mass:ProductAndServiceMember2021-01-012021-03-310001555279mass:ProductAndServiceMember2020-01-012020-03-310001555279mass:ProductAndServiceMembersrt:MinimumMember2021-01-012021-03-310001555279mass:ProductAndServiceMembersrt:MaximumMember2021-01-012021-03-310001555279srt:ScenarioForecastMembermass:WarrantsToPurchaseCommonStockMember2028-01-012028-12-310001555279srt:ScenarioForecastMembermass:WarrantsToPurchaseCommonStockMember2027-01-012027-12-3100015552792020-01-012020-03-3100015552792021-03-3100015552792020-12-310001555279us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001555279us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001555279us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001555279us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001555279mass:Revolver2021Member2021-03-110001555279mass:StockOptionAndIncentivePlan2020Member2021-01-012021-03-310001555279srt:MaximumMembermass:EmployeeStockPurchasePlan2020Member2021-01-012021-03-3100015552792021-04-3000015552792021-01-012021-03-31xbrli:sharesxbrli:pureiso4217:USDmass:customermass:Voteiso4217:USDxbrli:shares

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                     to                     .

Commission File Number: 001-39815

908 DEVICES INC.

(Exact name of registrant as specified in its charter)

Delaware

45-4524096

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

645 Summer Street, Boston, MA

02210

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (857) 254-1500

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange

  on which registered

Common Stock, par value $0.001 per share

MASS

The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  

Accelerated filer  

Non-accelerated filer    

Smaller reporting company  

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes      No  

As of April 30, 2021, the registrant had 27,300,154 shares of common stock, $0.001 par value per share, issued and outstanding.

Table of Contents

Table of Contents

Page

PART I.

FINANCIAL INFORMATION

4

Item 1.

Condensed Consolidated Financial Statements (Unaudited)

4

Condensed Consolidated Balance Sheets

4

Condensed Consolidated Statements of Operations and Comprehensive Loss

5

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

6

Condensed Consolidated Statements of Cash Flows

7

Notes to Unaudited Condensed Consolidated Financial Statements

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

20

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

33

Item 4.

Controls and Procedures

33

PART II.

OTHER INFORMATION

34

Item 1.

Legal Proceedings

34

Item 1A.

Risk Factors

34

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

34

Item 6.

Exhibits

35

Signatures

36

2

Table of Contents

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy and plans and our objectives for future operations, are forward-looking statements, and are made under the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “could,” “target,” “predict,” “seek” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those referenced in the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date of this report. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or to changes in our expectations.

We own various trademark registrations and applications, and unregistered trademarks, including MX908, Rebel, ZipChip and 908 Devices and our corporate logo. All other trade names, trademarks and service marks of other companies appearing in this Quarterly Report on Form 10-Q are the property of their respective holders. Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q may be referred to without the ®,™ or RTM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

3

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (Unaudited)

908 DEVICES INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share and per share amounts)

    

March 31, 

    

December 31, 

2021

2020

Assets

 

  

 

  

Current assets:

 

  

 

  

Cash and cash equivalents

$

148,959

$

159,227

Accounts receivable, net

 

4,367

 

6,825

Unbilled receivables

 

55

 

47

Inventory

 

6,822

 

4,568

Prepaid expenses and other current assets

 

2,696

 

300

Restricted cash

 

60

 

Total current assets

 

162,959

 

170,967

Operating lease, right-of-use assets

 

6,027

 

6,287

Property and equipment, net

 

966

 

850

Other long-term assets

 

1,798

 

723

Total assets

$

171,750

$

178,827

Liabilities and Stockholders' Equity

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable

$

1,690

$

1,004

Accrued expenses

 

3,011

 

5,038

Deferred revenue

 

3,321

 

3,104

Operating lease liabilities

 

1,225

 

1,187

Current portion of long-term debt

 

 

500

Total current liabilities

 

9,247

 

10,833

Long-term debt, net of discount and current portion

 

15,000

 

14,332

Operating lease liabilities, net of current portion

 

5,525

 

5,839

Deferred revenue, net of current portion

 

8,472

 

8,588

Other long-term liabilities

 

194

 

194

Total liabilities

 

38,438

 

39,786

Commitments and contingencies (Note 9)

 

  

 

  

Stockholders' equity:

 

  

 

  

Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding

 

 

Common stock, $0.001 par value; 100,000,000 shares authorized; 27,297,871 shares and 27,273,095 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively

 

27

 

27

Additional paid-in capital

 

217,848

 

217,482

Accumulated deficit

 

(84,563)

 

(78,468)

Total stockholders' equity

 

133,312

 

139,041

Total liabilities and stockholders' equity

$

171,750

$

178,827

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Table of Contents

908 DEVICES INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except share and per share amounts)

Three Months Ended March 31, 

2021

2020

Revenue:

  

    

  

Product and service revenue

$

5,357

$

2,639

License and contract revenue

 

186

 

1,362

Total revenue

 

5,543

 

4,001

Cost of revenue:

 

  

 

  

Product and service cost of revenue

 

2,560

 

1,570

License and contract cost of revenue

 

75

 

333

Total cost of revenue

 

2,635

 

1,903

Gross profit

 

2,908

 

2,098

Operating expenses:

 

  

 

  

Research and development

 

2,965

 

2,156

Selling, general and administrative

 

5,753

 

2,706

Total operating expenses

 

8,718

 

4,862

Loss from operations

 

(5,810)

 

(2,764)

Other income (expense):

 

  

 

  

Interest expense

 

(376)

 

(241)

Other income (expense), net

 

91

 

39

Total other expense, net

 

(285)

 

(202)

Net loss and comprehensive loss

 

(6,095)

 

(2,966)

Accretion of redeemable convertible preferred stock to redemption value

 

 

(30)

Net loss attributable to common stockholders

$

(6,095)

$

(2,996)

Net loss per share attributable to common stockholders, basic and diluted

$

(0.22)

$

(0.60)

Weighted average common shares outstanding, basic and diluted

 

27,290,364

 

4,993,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

Table of Contents

908 DEVICES INC.

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

(in thousands, except share amounts)

Redeemable Convertible

Additional

Total

Preferred Stock

Common Stock

Paid-in

Accumulated

Stockholders'

  

Shares

  

Amount

  

    

Shares

  

Amount

  

Capital

  

Deficit

  

Equity

Balances at December 31, 2020

$

27,273,095

$

27

$

217,482

$

(78,468)

$

139,041

Issuance of common stock upon exercise of stock options

 

 

24,776

 

 

27

 

 

27

Stock-based compensation expense

 

 

 

 

339

 

 

339

Net loss

 

 

 

 

 

(6,095)

 

(6,095)

Balances at March 31, 2021

 

$

27,297,871

$

27

$

217,848

$

(84,563)

$

133,312

Redeemable Convertible

Additional

Total

Preferred Stock

Common Stock

Paid-in

Accumulated

Stockholders'

  

Shares

  

Amount

  

  

Shares

  

Amount

  

Capital

  

Deficit

  

Equity (Deficit)

Balances at December 31, 2019

23,905,267

$

71,017

4,990,702

$

5

$

2,476

$

(65,649)

$

(63,168)

Accretion of redeemable convertible preferred stock to redemption value

 

 

30

 

 

(30)

 

 

(30)

Issuance of common stock upon exercise of stock options

 

 

3,007

 

 

3

 

 

3

Stock-based compensation expense

 

 

 

 

66

 

 

66

Net loss

 

 

 

 

 

(2,966)

 

(2,966)

Balances at March 31, 2020

 

$

71,047

4,993,709

$

5

$

2,515

$

(68,615)

$

(66,095)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

Table of Contents

908 DEVICES INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

Three Months Ended March 31, 

2021

2020

Cash flows from operating activities:

    

  

    

  

Net loss

$

(6,095)

$

(2,966)

Adjustments to reconcile net loss to net cash used in operating activities:

 

  

 

  

Depreciation and amortization expense

 

137

 

205

Stock-based compensation expense

 

339

 

66

Change in fair value of preferred stock warrant liability

 

 

23

Noncash interest expense and loss on extinguishment of debt

 

168

 

16

Provision for inventory obsolescence

 

(29)

 

42

Changes in operating assets and liabilities:

 

  

 

  

Accounts receivable, net

 

2,458

 

987

Unbilled receivables

 

(8)

 

(294)

Inventory

 

(2,469)

 

(1,010)

Prepaid expenses and other current assets

 

(2,396)

 

61

Other long-term assets

 

(1,036)

 

(4)

Accounts payable and accrued expenses

 

(787)

 

(151)

Deferred revenue

 

101

 

(138)

Right-of-use operating lease assets

 

276

 

254

Operating lease liabilities

 

(292)

 

(259)

Net cash used in operating activities

 

(9,633)

 

(3,168)

Cash flows from investing activities:

 

  

 

  

Purchases of property and equipment

 

(9)

 

(91)

Net cash used in investing activities

 

(9)

 

(91)

Cash flows from financing activities:

 

  

 

  

Proceeds from issuance of common stock upon option exercise

 

27

 

3

Payments of public offering costs

 

(576)

 

Proceeds from issuance of revolving line of credit

 

15,000

 

Repayment of notes payable

 

(15,000)

 

Payments of debt issuance costs

(17)

Net cash provided by (used in) financing activities

 

(566)

 

3

Net decrease in cash, cash equivalents and restricted cash

 

(10,208)

 

(3,256)

Cash, cash equivalents and restricted cash at beginning of period

 

159,227

 

17,913

Cash, cash equivalents and restricted cash at end of period

$

149,019

$

14,657

Supplemental disclosure of noncash investing and financing information:

 

  

 

  

Transfers of inventory to property and equipment

$

244

$

Accretion of redeemable convertible preferred stock to redemption value

$

$

30

Debt issuance costs in accounts payable and accrued expenses

$

22

$

Operating right of use assets arising from operating lease liabilities

$

16

$

Reconciliation of cash, cash equivalents and restricted cash:

 

  

 

  

Cash and cash equivalents

$

148,959

$

14,657

Restricted cash

 

60

 

Total cash, cash equivalents and restricted cash shown in the statement of cash flows

$

149,019

$

14,657

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

7

Table of Contents

908 DEVICES INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Nature of the Business and Basis of Presentation

908 Devices Inc. (the “Company”) was incorporated in the State of Delaware on February 10, 2012. The Company is a commercial-stage technology company providing a suite of purpose-built handheld and desktop mass spectrometry devices for the point-of-need to interrogate unknown and invisible materials in a broad array of markets including life sciences research, bioprocessing, industrial biotech, forensics and adjacent markets.

The Company is subject to risks and uncertainties common to technology companies in the device industry and of similar size, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, and the need to obtain additional financing to fund operations. Potential risks and uncertainties also include, without limitation, uncertainties regarding the duration and magnitude of the impact of the COVID-19 pandemic on the Company’s business and the economy generally. Products currently under development will require additional research and development efforts prior to commercialization and will require additional capital and adequate personnel and infrastructure. The Company’s research and development may not be successfully completed, adequate protection for the Company’s technology may not be obtained, the Company may not obtain necessary government regulatory approval, and approved products may not prove commercially viable. The Company operates in an environment of rapid change in technology and competition.

In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (“COVID-19”) outbreak a pandemic. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. The Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its future financial condition and operations. The impact of the COVID-19 coronavirus outbreak on the Company’s financial performance will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s results may be materially adversely affected.

Future impacts to the Company’s business as a result of COVID-19 could include disruptions to the Company’s manufacturing operations and supply chain caused by facility closures, reductions in operating hours, staggered shifts and other social distancing efforts; labor shortages; decreased productivity and unavailability of materials or components; limitations on its employees’ and customers’ ability to travel, and delays in shipments to and from affected countries and within the United States. While the Company maintains an inventory of finished products and raw materials used in its products, a prolonged pandemic could lead to shortages in the raw materials necessary to manufacture its products.

On December 22, 2020, the Company completed its initial public offering (“IPO”), pursuant to which it issued and sold 7,475,000 shares of common stock, inclusive of 975,000 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares. The Company received net proceeds of $136.6 million after deducting underwriting discounts and commissions and other offering costs. Upon the closing of the IPO, all of the shares of the Company’s outstanding redeemable convertible preferred stock then outstanding automatically converted into 14,691,929 shares of common stock.

Basis of Presentation

The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable

8

Table of Contents

guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, 908 Devices Securities Corporation. All intercompany balances and transactions have been eliminated.

The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since inception, including net losses of $6.1 million for the three months ended March 31, 2021 and $12.8 million for the year ended December 31, 2020. As of March 31, 2021, the Company had an accumulated deficit of $84.6 million. The Company expects to continue to generate operating losses in the foreseeable future. The Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of the condensed consolidated financial statements. The Company may seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product expansion or commercialization efforts, or the Company may be unable to continue operations. Although management continues to pursue these financing plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.

2. Summary of Significant Accounting Policies

Unaudited Interim Financial Information

The condensed consolidated balance sheet at December 31, 2020 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of March 31, 2021 and for the three months ended March 31, 2021 and 2020 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 on file with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s financial position as of March 31, 2021 and results of operations for the three months ended March 31, 2021 and 2020 and cash flows for the three months ended March 31, 2021 and 2020 have been made. The Company’s results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2021 or any other period.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the valuation of inventory and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of these condensed consolidated financial statements. These estimates may change, as new events occur and

9

Table of Contents

additional information is obtained. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.

Concentrations of Credit Risk and of Significant Customers

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents with two financial institutions that management believes to be of high credit quality. The Company has not experienced any other-than-temporary losses with respect to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

Significant customers are those that accounted for 10% or more of the Company’s total revenue or accounts receivable. During the three months ended March 31, 2021, two customers represented 19% and 10% of total revenue, respectively. During the three months ended March 31, 2020, two customers represented 32% and 12% of total revenue, respectively. As of March 31, 2021, two customers accounted for 39% and 14%, respectively, of gross accounts receivable. As of December 31, 2020, three customers accounted for 27%, 11% and 11%, respectively, of gross accounts receivable. The credit and economic conditions within countries in Europe, Middle East and Africa that the Company does business with have been weak in recent years. These conditions have continued to deteriorate as a result of COVID-19 and may continue to increase the average length of time that it takes to collect on the accounts receivables outstanding in these countries. As of March 31, 2021, the gross accounts receivable balance from these countries amount to $2.2 million, the majority of which is more than 90 days past due. The Company is actively pursuing collection of all amounts past due, however, if the Company is unable to collect these amounts, then an allowance would have to be recorded.

Certain of the components included in the Company’s products are obtained from a sole source, a single source or a limited group of suppliers. Although the Company seeks to reduce dependence on those limited sources of suppliers and manufacturers, the partial or complete loss of certain of these sources, or the requirement to establish a new supplier for the components, could have a material adverse effect on the Company’s operating results, financial condition and cash flows and damage its customer relationships.

Fair Value Measurements

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

Level 1 — Quoted prices in active markets for identical assets or liabilities.
Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The Company’s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s accounts receivable, unbilled receivables, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The carrying value of the Company’s long-term debt approximates its fair value (a level 2 measurement) at each balance sheet date due to its variable interest rate, which approximates a market interest rate.

10

Table of Contents

Revenue Recognition

The Company recognizes revenue from sales to customers under ASC 606, Revenue from Contracts with Customers (“ASC 606”), by applying the following five steps: (1) identification of the contract, or contracts, with a customer, (2) identification of the performance obligations in the contract, (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligations in the contract and (5) recognition of revenue when, or as, performance obligations are satisfied.

Product and Service Revenue

The Company derives product and service revenue primarily from the sale of handheld and desktop products and related consumables and services. Revenue is recognized when control of the promised products, consumables or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products, consumables or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of accounting under ASC 606. For devices and consumables sold by the Company, control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment, legal title must have passed to the customer, the customer must have the significant risks and rewards of ownership, and where acceptance is other than perfunctory, the customer must have accepted the product or service. The Company’s principal terms of sale are freight on board (“FOB”) shipping point, or equivalent, and, as such, the Company primarily transfers control and records revenue for product sales upon shipment. Sales arrangements with delivery terms that are not FOB shipping point are not recognized upon shipment and the transfer of control for revenue recognition is evaluated based on the associated shipping terms and customer obligations. If a performance obligation to the customer with respect to a sales transaction remains to be fulfilled following shipment (typically installation or acceptance by the customer), revenue recognition for that performance obligation is deferred until such commitments have been fulfilled. For extended warranty and support, control transfers to the customer over the term of the arrangement. Revenue for extended warranty and support is recognized based upon the period of time elapsed under the arrangement as this period represents the transfer of benefits or services under the agreement.

For a contract with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on a relative standalone selling price basis using the Company’s best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the price observed in standalone sales to customers; however, when prices in standalone sales are not available the Company may use third party pricing for similar products or services or estimate the standalone selling price, which is set by management. Allocation of the transaction price is determined at the contract’s inception.

The Company recognizes a receivable at the point in time at which it has an unconditional right to payment. Such receivables are not contract assets. Payment terms for customer orders, including for each of the Company’s primary performance obligations, are typically 30 to 90 days after the shipment or delivery of the product, and such payments typically do not include payments that are variable, dependent on specified factors or events. In limited circumstances, there exists a right of return for product if agreed to by the Company. Revenue is only recognized for those goods that are not expected to be returned such that it is probable that there will not be a significant reversal of cumulative revenue. Service arrangements commonly call for payments in advance of performing the work (e.g., extended warranty/service contracts), upon completion of the service or a mix of both. The Company does not enter into significant financing agreements or other forms of variable consideration.

Contract assets arise from unbilled amounts in customer arrangements when revenue recognized exceeds the amount billed to the customer and the Company’s right to payment is not only subject to the passage of time. The Company had no contract assets related to product or service revenue as of March 31, 2021 or December 31, 2020.

Contract liabilities represent the Company’s obligation to transfer goods or services to a customer for which it has received consideration (or the amount is due) from the customer. The Company has determined that its only contract liability related to product and service revenue is deferred revenue, which consists of amounts that have been invoiced but that have not been recognized as revenue. Amounts expected to be recognized as revenue within 12 months of the

11

Table of Contents

balance sheet date are classified as current deferred revenue and amounts expected to be recognized as revenue beyond 12 months of the balance sheet date are classified as noncurrent deferred revenue.

The following is a summary of the activity of the Company’s deferred revenue related to product and service revenue (in thousands):

    

Three Months Ended March 31, 

2021

2020

Balances at beginning of period

$

8,938

$

1,509

Recognition of revenue included in balance at beginning of the period

 

(760)

 

(263)

Revenue deferred during the period, net of revenue recognized

 

920

 

677

Balances at end of period

$

9,098

$

1,923

The amount of deferred revenue equals the transaction price allocated to unfulfilled performance obligations for the period presented. Such deferred revenue amounts related to product and service revenue are expected to be recognized in the future as follows (in thousands):

    

March 31, 

2021

Deferred revenue expected to be recognized in:

 

  

One year or less

$

3,126

One to two years

 

1,964

Three years and beyond

 

4,008

$

9,098

License and Contract Revenue

The Company generates revenue from short and long-term contracts associated with the design and development and delivery of detection devices or related design and support services. To date, these contracts are primarily with the U.S. government or commercial entities contracting with the U.S. government, but the Company has also had such contracts with commercial partners. The Company’s contracts with the U.S. government typically are subject to the Federal Acquisition Regulation (“FAR”) and are priced based on estimated or actual costs of producing goods or providing services. The FAR provides guidance on the types of costs that are allowable in establishing prices for goods or services provided under U.S. government contracts. The pricing for non-U.S. government contracts is based on the specific negotiations with each customer.

Under the typical payment terms of U.S. government fixed-price contracts, the customer pays in accordance with the terms of the specific agreement, but generally through progress payments. If these progress payments are made in advance, these payments are recorded as a contract liability, classified as deferred revenue within the accompanying condensed consolidated balance sheet, until the Company provides the underlying services. For U.S. government cost-type contracts, the customer generally pays for actual costs incurred within a short period of time. For contracts with commercial partners, payments are made in accordance with the terms of the specific agreement. For agreements which call for milestone payments, to the extent the Company does not conclude that it is probable that a significant reversal of cumulative revenue will occur, a contract asset is generated until the Company is permitted to bill for costs incurred, which is classified as unbilled receivables in the accompanying condensed consolidated balance sheet. In some cases, payments received in advance under license agreements are recorded as deferred revenue and recognized over the respective contract term, absent any other performance obligations.

Generally, revenue for long-term contracts is recognized based upon the cost-to-cost measure of progress, provided that the Company meets the criteria associated with transferring control of the good or service over time such as not creating an asset with an alternative use and having an enforceable right to payment for completed performance. However, the Company evaluates the proper revenue recognition on a contract by contract basis, as each contract generally contains terms specific to the underlying agreement which result in differing performance obligations and payment terms (cost plus, fixed price agreements among others). For revenue recognized under the cost-to-cost measure

12

Table of Contents

of progress basis, the Company continually assesses total costs expected to be incurred and if such costs require adjustment to the measure of progress, the Company records such adjustment as a change in estimate on a cumulative catch-up basis in the period of adjustment.

The Company includes the unconstrained amount of consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, as required under ASC 606, the Company re-evaluates the estimated consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.

Contract assets arise from unbilled amounts in customer arrangements when revenue recognized exceeds the amount billed to the customer and the Company’s right to payment is not just subject to the passage of time. The Company includes contract assets within unbilled receivables in the accompanying condensed consolidated balance sheet. As of March 31, 2021 and December 31, 2020, the Company had contract assets related to contract or license revenue totaling less than $0.1 million.

Contract liabilities represent the Company’s obligation to transfer goods or services to a customer for which it has received consideration (or the amount is due) from the customer. Contract liabilities arising from license agreements typically represent payments received for the license of symbolic intellectual property for a defined term. As of March 31, 2021, the Company had contract liabilities totaling $2.7 million related to contract and license revenue, which the Company expects to recognize during the years ended December 31, 2021 and 2022. As of December 31, 2020, the Company had contract liabilities totaling $2.8 million related to contract and license revenue, of which the Company recognized $0.1 million during the three months ended March 31, 2021. The Company recognizes deferred revenue by first allocating from the beginning deferred revenue balance to the extent that the beginning deferred revenue balance exceeds the revenue to be recognized. Billings during the period are added to the deferred revenue balance to be recognized in future periods. As of March 31, 2021, the Company’s wholly- or partially-unsatisfied performance obligations totaled $0.7 million related to contract and license agreements entered into prior to period end, which the Company expects to recognize during the years ended December 31, 2021 and 2022.

Distribution Channels

A majority of the Company’s revenue is generated by sales in conjunction with its distribution partners, such as its international distributors and, in the United States, for end customers where a government contract is required or a customer has a pre-existing relationship. When the Company transacts with a distribution partner, its contractual arrangement is with the partner and not with the end-use customer. Whether the Company transacts business with and receives the order from a distribution partner or directly from an end-use customer, its revenue recognition policy and resulting pattern of revenue recognition for the order are the same.

Disaggregated Revenue

The Company’s product and service revenue consists of sales of devices and consumables and the sale of service and extended warranty plans. The following table presents the Company’s revenue by revenue stream (in thousands):

    

Three Months Ended March 31, 

2021

2020

Product and service revenue:

 

  

 

  

Device sales revenue

$

3,911

$

1,988

Consumables and service revenue

 

1,446

 

651

Total product and service revenue

 

5,357

 

2,639

License and contract revenue

 

186

 

1,362

Total revenue

$

5,543

$

4,001

13

Table of Contents

The following table presents the Company’s product and service revenue by device type (in thousands):

    

Three Months Ended March 31, 

2021

2020

Handheld

$

3,240

$

1,540

Desktop

 

2,117

 

1,099

Total product and service revenue

$

5,357

$

2,639

Revenue based on the end-user entity type for the Company’s product and service revenue are presented below (in thousands):

    

Three Months Ended March 31, 

2021

2020

Government

$

3,234

$

1,445

Pharmaceutical/Biotechnology

 

2,100

 

1,183

Academia

 

23

 

11

Total product and service revenue

$

5,357

$

2,639

The following table disaggregates the Company’s revenue from contracts with customers by geography, which are determined based on the customer location (in thousands):

    

Three Months Ended March 31, 

2021

2020

North America

$

4,674

$

3,382

Europe, Middle East and Africa

 

446

 

421

Asia Pacific

 

423

 

198

$

5,543

$

4,001

International sales are comprised of product and service revenue, with all license and contract revenue being attributable to North America.

Net Income (Loss) per Share

Prior to the closing of its IPO, the Company followed the two-class method when computing net income (loss) per share, as they had issued shares that met the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The outstanding convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses were not allocated to such participating securities, and as a result, basic and diluted net loss per share were the same.

Under the two-class method, basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.

14

Table of Contents

Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.

The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

    

March 31, 

2021

2020

Redeemable convertible preferred stock (as converted to common stock)

 

 

14,691,929

Warrants for the purchase of redeemable convertible preferred stock (as converted to common stock)

 

 

154,634

Warrants to purchase common stock

 

92,703

 

Options to purchase common stock

 

3,401,557

 

2,271,315

 

3,494,260

 

17,117,878

Recently Issued Accounting Pronouncements

The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to “opt out” of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company will adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326). The new standard adjusts the accounting for assets held at amortized costs basis, including marketable securities accounted for as available for sale, and trade receivables. The standard eliminates the probable initial recognition threshold and requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For public entities except smaller reporting companies, the guidance was effective for annual reporting periods beginning after December 15, 2019 and for interim periods within those fiscal years. For non-public entities and smaller reporting companies, the guidance was effective for annual reporting periods beginning after December 15, 2021. In November 2019, the FASB issued ASU No. 2019-10, which deferred the effective date for non-public entities to annual reporting periods beginning after December 15, 2022, including interim periods within those fiscal years. Early application is allowed. The Company is currently assessing the impact of the adoption of this guidance on its condensed consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various areas related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in ASC 740 and also clarifies and amends existing guidance to improve consistent application. For public entities the guidance was effective for annual reporting periods beginning after December 15, 2020 and for interim periods within those fiscal years. For non-public entities, the guidance is effective for annual reporting periods beginning after December 15, 2021 and for interim periods within years beginning after December 15, 2022, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this guidance on its condensed consolidated financial statements.

15

Table of Contents

3. Fair Value Measurements

The following tables present the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis (in thousands):

Fair Value Measurements at March 31, 2021 Using:

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets:

 

  

 

  

 

  

 

  

Cash equivalents:

 

  

 

  

 

  

 

  

Money market funds

$

43

$

$

$

43

Fair Value Measurements at December 31, 2020 Using:

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets:

 

  

 

  

 

  

 

  

Cash equivalents:

 

  

 

  

 

  

 

  

Money market funds

$

339

$

$

$

339

Money market funds were valued by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. There were no transfers into or out of Level 3 during the three months ended March 31, 2021 or 2020.

4. Inventory

Inventory consisted of the following (in thousands):

    

March 31, 

    

December 31, 

2021

2020

Raw materials

$

3,104

$

2,099

Work-in-progress

 

1,800

 

213

Finished goods

 

1,918

 

2,256

$

6,822

$

4,568

5. Accrued Expenses

Accrued expenses consisted of the following (in thousands):

    

March 31, 

    

December 31, 

2021

2020

Accrued employee compensation and benefits

$

786

$

2,069

Accrued warranty

 

1,086

 

1,265

Accrued professional fees

 

729

 

975

Accrued other

 

410

 

729

$

3,011

$

5,038

Changes in the Company’s product warranty obligation were as follows (in thousands):

Three Months Ended March 31, 

    

2021

    

2020

Accrual balance at beginning of period

$

1,265

$

968

Provision for new warranties

 

198

 

107

Settlements and adjustments made during the period

 

(377)

 

(168)

Accrual balance at end of period

$

1,086

$

907

16

Table of Contents

6. Long-Term Debt

Long-term debt consisted of the following (in thousands):

    

March 31, 

    

December 31, 

2021

2020

Principal amount of long-term debt

$

15,000

$

15,000

Less: Current portion of long-term debt

 

 

(500)

Long-term debt, net of current portion

 

15,000

 

14,500

Debt discount, net of accretion

 

 

(168)

Long-term debt, net of discount and current portion

$

15,000

$

14,332

As of December 31, 2020, the Company had outstanding borrowings under a Loan and Security Agreement, as amended (the “2019 Loan”) with a financial institution (the “Lender”). On March 11, 2021, the Company entered into an Amended and Restated Loan and Security Agreement, (the “2021 Revolver”), with the Lender to replace the 2019 Loan. This agreement created a revolving line of credit totaling $25.0 million and eliminated the existing term loan. Borrowings under the revolving line of credit bear interest at an annual rate equal to the greater of (i) one-half percent (0.5%) above the prime rate or (ii) 4.0% and mature on March 11, 2024. Borrowings are collateralized by substantially all of the Company’s property, excluding intellectual property, which is subject to a negative pledge. The 2021 Revolver subjects the Company to various customary covenants, including requirements as to financial reporting and financial covenants (including an unrestricted minimum cash level of $10.0 million), and restrictions on the Company’s ability to dispose of its business or property, to change its line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on the Company’s property, to pay any dividends or make other distributions on capital stock other than dividends payable solely in capital stock, to redeem capital stock, to enter into in-bound licensing agreements, to engage in transactions with affiliates, and to encumber the Company’s intellectual property. Events of default under the 2021 Revolver include failure to make payments when due, insolvency events, failure to comply with covenants or material adverse events with respect to the Company. Upon the occurrence of an event of default and until such event of default is no longer continuing, the annual interest rate will be 5.0% above the otherwise applicable rate. As of March 31, 2021, the Company was in compliance with all financial covenants under the 2021 Revolver.

The terms of the 2021 Revolver required that the existing term loan outstanding under the 2019 Loan be repaid with an advance under the line of credit. Accordingly, on March 11, 2021, the Company used $14.5 million of proceeds from the revolving line of credit to repay all amounts then due on the existing term loan. The Company also borrowed an additional $0.5 million from the 2021 Revolver in March 2021.

The Company accounted for the transaction as a debt extinguishment and recorded a loss on extinguishment of $0.2 million, which was included in interest expense in the condensed consolidated statements of operations and comprehensive loss.

7. Equity

As of March 31, 2021, the Company’s certificate of incorporation authorized the Company to issue shares of preferred stock, all of which is undesignated.

Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.

As of March 31, 2021 and December 31, 2020, the Company had outstanding warrants for the purchase of 92,703 shares of common stock at an exercise price of $9.17 per share, of which warrants for the purchase of 49,078 shares and 43,625 shares expire in 2027 and 2028, respectively.

17

Table of Contents

8. Stock-Based Compensation

2020 Stock Option and Incentive Plan

On November 23, 2020, the Company’s board of directors adopted, and on December 11, 2020, the Company’s stockholders approved the 2020 Stock Option and Incentive Plan (the “2020 Stock Plan”), which became effective on December 17, 2020. The 2020 Stock Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, unrestricted stock units, dividend equivalent rights and cash-based awards to employees, directors and consultants of the Company. The total number of shares of common stock that may be issued under the 2020 Plan is 1,843,771 shares plus the number of shares underlying awards under the previously outstanding 2012 Stock Option and Grant Plan (the “2012 Plan”) that expire or are terminated, surrendered, or cancelled without the delivery of shares, are forfeited to or repurchased or otherwise become available again for grant under the 2012 Plan. As of March 31, 2021, 1,860,629 shares remained available for future issuance under the 2020 Plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the 2020 Plan will automatically increase on January 1, 2022 and each January 1 thereafter, by 4% of the outstanding number of shares of our common stock on the immediately preceding December 31 or such lesser number of shares as determined by the administrator of the 2020 Stock Plan.

2020 Employee Stock Purchase Plan

On November 23, 2020, the Company’s board of directors adopted, and on December 11, 2020, the Company’s stockholders approved the 2020 Employee Stock Purchase Plan (the “2020 ESPP”), which became effective on December 17, 2020. A total of 288,857 shares of common stock of the Company are reserved for issuance under the 2020 ESPP. As of March 31, 2021, 288,857 shares remained available for issuance under the 2020 ESPP. The 2020 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2022 and each January 1 thereafter through January 1, 2030, by the least of (i) 307,295 shares of our common stock, (ii) 1% of the outstanding number of shares of common stock on the immediately preceding December 31, or (iii) such lesser number of shares of common stock as determined by the administrator of the 2020 ESPP. As of March 31, 2021, no offering periods have commenced under the 2020 ESPP.

Stock-Based Compensation

The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss (in thousands):

Three Months Ended March 31, 

    

2021

    

2020

Cost of revenue

$

3

$

2

Research and development expenses

 

60

 

17

Selling, general and administrative expenses

 

276

 

47

$

339

$

66

As of March 31, 2021, unrecognized compensation expense was $4.4 million, which is expected to be recognized over a weighted average period of 3.26 years.

9. Commitments and Contingencies

Operating Leases

The Company’s primary operating lease obligations consists of various leases for office space in Boston, Massachusetts; North Carolina; and Pennsylvania.

18

Table of Contents

There have been no material changes to the Company’s leases during the three months ended March 31, 2021. For additional information, please read Note 12, Leases, to the consolidated financial statements in the Company’s Form 10-K for the year ended December 31, 2020.

Royalty Arrangements

The Company has entered into royalty arrangements with two parties whereby the Company owes low- to mid-single digit royalty percentages related to revenue that is derived pursuant to in-licensed technologies. Royalty obligations are expensed when incurred or over the minimum royalty periods and have not been material. Some of the arrangements include minimum royalties over a defined term.

The future minimum royalty payments are $0.1 million per year through the end of the patents’ lives. The Company has the right to terminate the agreements with written notice.

401(k) Savings Plan

The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions to the plan may be made at the discretion of the board of directors. As of March 31, 2021, the Company had not made any contributions to the plan.

Indemnification Agreements

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with its executive officers and members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or services as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and had not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of March 31, 2021.

Legal Proceedings

The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.

19

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC (“2020 Form 10-K”). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in “Item 1.A. Risk Factors” section of our 2020 Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We have developed an innovative suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Leveraging our proprietary platform technology, we make the extraordinary analytical power of Mass Spec available in devices that are significantly smaller and more accessible than conventional laboratory instruments. Our Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, industrial biotech, forensics and adjacent markets.

We create simplified measurement devices that our customers can use as accurate tools where and when their work needs to be done, rather than overly complex and centralized analytical instrumentation. We believe the insights and answers our devices provide will accelerate workflows, reduce costs, and offer transformational opportunities for our end users.

Front-line workers rely upon our handheld devices to combat the opioid crisis and detect counterfeit pharmaceuticals and illicit materials in the air or on surfaces at levels 1,000 times below their lethal dose. Our desktop devices are accelerating development and production of biotherapeutics by identifying and quantifying extracellular species in bioprocessing critical to cell health and productivity. They sit alongside bioreactors and fermenters producing drug candidates, functional proteins, cell and gene therapies, and synthetic biology derived products. We believe the insights and answers our devices provide accelerate workflows, reduce costs, and offer transformational opportunities for our end users. The term “products” as used in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” refers to the MX908, Rebel and ZipChip Interface.

Since inception, we have focused substantially all of our resources on designing, developing and building our proprietary Mass Spec platform and associated technologies, supporting software improvements and data analysis, organizing and staffing our company, planning our business, raising capital, and providing general and administrative support for these operations. To date, we have funded our operations primarily with proceeds from sales of preferred stock and borrowings under loan agreements and, most recently, with proceeds from our initial public offering, or IPO. On December 22, 2020, we completed our IPO, pursuant to which we issued and sold 7,475,000 shares of common stock, inclusive of 975,000 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares. We received net proceeds of $136.6 million after deducting underwriting discounts and commissions and other offering costs.

Since our inception, we have incurred significant operating losses. Our ability to generate revenue sufficient to achieve profitability will depend on the successful further development and commercialization of our products. We generated revenue of $5.5 million and incurred net losses of $6.1 million for the three months ended March 31, 2021. We generated revenue of $26.9 million and incurred net losses of $12.8 million for the year ended December 31, 2020. As of March 31, 2021, we had an accumulated deficit of $84.6 million. We expect to continue to incur net losses as we focus on growing commercial sales of our products in both the United States and international markets, including growing our sales teams, scaling our manufacturing operations, continuing research and development efforts to develop new products and further enhance our existing products. Further, we expect to incur additional costs associated with

20

Table of Contents

operating as a public company. As a result, we will need substantial additional funding for expenses related to our operating activities, including selling, general and administrative expenses and research and development expenses.

Because of the numerous risks and uncertainties associated with product development and commercialization, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Until such time, if ever, as we can generate substantial revenue sufficient to achieve profitability, we expect to finance our operations through a combination of equity offerings, debt financings and strategic alliances. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we are unable to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the further development and commercialization efforts of one or more of our products, or may be forced to reduce or terminate our operations.

We believe that our existing cash and cash equivalents, will enable us to fund our operating expenses, capital expenditure requirements and debt service payments into 2023. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See “Liquidity and Capital Resources.”

COVID-19

In December 2019, a novel strain of coronavirus, or COVID-19, emerged in Wuhan, Hubei Province, China. Less than four months later, in March 2020, the World Health Organization declared COVID-19 a pandemic, and the virus has now spread to many other countries and regions and every state within the United States, including Massachusetts, where our primary offices and manufacturing facility are located. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.

In 2020, we had impacts to our business as a result of COVID-19 including disruptions to our manufacturing operations and supply chain caused by facility closures, reductions in operating hours, staggered shifts and other social distancing efforts, decreased productivity and unavailability of materials or components, limitations on our employees’ and customers’ ability to travel, and delays in product installations, trainings or shipments to and from affected countries and within the United States.

In 2021, we are seeing an increase in desktop customer activity in the lab and customers enabling on site installations and trainings. However, we are continuing to experience extended lead times on our supply chain and limitations on travel, among other disruptions we experienced in 2020.

We do not yet know the net impact that the COVID-19 pandemic may have on our business and cannot guarantee that it will not be materially negative. Although we continue to monitor the situation and may adjust our current policies as more information and public health guidance become available, the ongoing effects of the COVID-19 pandemic and/or the precautionary measures that we have adopted may create operational and other challenges, any of which could harm our business and results of operations. While we maintain an inventory of finished products and raw materials used in our products, a prolonged pandemic could lead to shortages in the raw materials necessary to manufacture our products. If we experience a prolonged disruption in our manufacturing, supply chains or commercial operations, or if demand for our products is significantly reduced as a result of the COVID-19 pandemic, we would expect to experience a material adverse impact on our business, financial condition, results of operations and prospects.

Historically, a significant portion of our field sales, customer training events and other application services have been conducted in person, and the rollout of our new products has historically been supported by our participation at industry conferences. Currently, as a result of the work and travel restrictions related to the COVID-19 pandemic, and the precautionary measures that we have adopted, substantially all of our field sales and professional services activities are being conducted remotely, which has resulted in a decrease in our travel expenditures. However, we expect our travel expenditures to increase in the future, which could negatively impact our financial condition and results of operations. We do not yet know the extent of the negative impact of such restrictions and precautionary measures on our ability to attract new customers or retain and expand our relationships with existing customers over the near and long term.

21

Table of Contents

Factors affecting our performance

We believe that our financial performance has been and in the foreseeable future will continue to be primarily driven by the following factors. While each of these factors presents significant opportunities for our business, they also pose important challenges that we must successfully address in order to sustain our growth and improve our results of operations. Our ability to successfully address the factors below is subject to various risks and uncertainties.

Device sales

Our financial performance has largely been driven by, and in the future will continue to be impacted by, the rate of sales of our handheld and desktop devices. Management focuses on device sales as an indicator of current business success and a leading indicator of likely future recurring revenue from consumables and services. We expect our device sales to continue to grow as we increase penetration in our existing markets and expand into, or offer new features and solutions that appeal to, new markets.

We plan to grow our device sales in the coming years through multiple strategies including expanding our sales efforts domestically and globally and continuing to enhance the underlying technology and applications for life sciences research related to our Rebel and ZipChip Interface. We regularly solicit feedback from our customers and focus our research and development efforts on enhancing our devices and enabling our customers to use additional applications that address their needs, which we believe in turn helps to drive additional sales of our devices and consumables.

Our sales process varies considerably depending upon the type of customer to whom we are selling. Historically, our handheld devices have been used by state, federal and foreign governments and governmental agencies. Our sales process with government customers is often long and involves multiple levels of approvals, testing and, in some cases, trials. Device orders from a government customer are typically large orders and can be impacted by the timing of their capital budgets. As a result, the revenue for our handheld devices can vary significantly from period-to-period and has been and may continue to be concentrated in a small number of customers in any given period.

Our desktop devices are typically used by the pharmaceutical, biotechnology and academia markets. Our sales cycles within these markets tend to vary based on the size of the customer and the number of devices they purchase. Our shortest sales cycles are typically for small laboratories and individual researchers where, in some cases, we receive purchase orders from these customers within three months. Our sales process with other institutions can be longer with most customers submitting purchase orders within six to twelve months. Given the variability of our sales cycle, we have in the past experienced, and likely will in the future experience, fluctuations in our desktop device sales on a period-to-period basis. Additionally, we have experienced and may continue to experience the impact of laboratory shutdowns related to COVID-19 on device and consumable sales to these markets.

Recurring revenue

We regularly assess trends relating to recurring revenue which includes consumables and services based on our product offerings, our customer base and our understanding of how our customers use our products. Consumables and service revenue was 27% and 25% of total product and service revenue for the three months ended March 31, 2021 and 2020, respectively. Our recurring revenue as a percentage of total product and service revenue will vary based upon new device placements in the period. As our device installed base expands, recurring revenue on an absolute basis is expected to increase and over time should be an increasingly important contributor to our revenue.

Revenue from the sales of consumables will vary by type of device. We expect that consumables and service revenue as a percentage of the original device price to be higher for our desktop devices (Rebel and ZipChip Interface) than for our handheld device (MX908). While we sell single-use swab samplers for MX908 to be used in liquid and solid materials analysis, there are a number of other applications that the MX908 can be used for that do not require consumables. Rebel and ZipChip Interface require consumables kits for all areas of operations. Currently, Rebel customers, who are actively utilizing the device, are consuming on average one 200-sample kit per month; however, Rebel is a new product and purchasing patterns related to our consumables kits are evolving. We expect that the number of kits sold per month will vary over the short term. In time, we expect Rebel consumables kits sales to become more

22

Table of Contents

consistent as our installed base grows and our customers establish usage patterns. At maximum potential capacity, with continuous operation, the Rebel can consume approximately one 200-sample kit per day.

Revenue mix and gross margin

Our revenue is derived from sales of our devices, consumables and services. There will be fluctuations in mix between devices and consumables from period-to-period. Over time, as our device installed base grows and we see adoption of Rebel, we expect consumables revenue to constitute a larger percentage of product and service revenue. However, the percentage will be subject to fluctuation based upon our handheld sales in a period. In addition, our selling price and, consequently, our margins, are higher for those devices and consumables that we sell directly to customers as compared to those that we sell through distributors. While we expect the mix of direct sales as compared to sales through distributors to remain relatively constant in the near term, we are currently evaluating increasing our direct sales capabilities in certain geographies.

Future device and consumable selling prices and gross margins may fluctuate due to a variety of factors, including the introduction by others of competing products and solutions. We aim to mitigate downward pressure on our average selling prices by increasing the value proposition offered by our devices and consumables, primarily by expanding the applications for our devices and increasing the quantity and quality of data that can be obtained using our consumables.

Product adoption

We monitor our customers’ stage of adoption of our products to provide insight into the timing of future potential sales and to help us formulate financial projections. Typical stages of adoption include testing, trials, pilot and deployment as follows:

Testing—a customer is actively engaged with internal or external testing of our products. This may include an onsite or virtual demonstration with a salesperson, a customer submitting samples for testing in one of our facilities or testing by a third party.
Trials—a customer has committed to a trial of one of our products, which may include a defined period to assess functionality of the device in their operational environment (in the field or onsite within the customer’s facility).
Pilot—a customer commits to the purchase of an initial quantity of devices to deploy in their operational environment to assess a broader opportunity that may grow to tens or hundreds of devices.
Deployment—a customer has completed testing, a trial, and/or a pilot and intends to roll out the technology across their enterprise (either at a site or throughout the entire organization).

Key Business Metrics

We regularly review the number of product placements and cumulative product placements as key metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections, and make strategic decisions. We believe that these metrics are representative of our current business; however, we anticipate these will change or may be substituted for additional or different metrics as our business grows.

During the three months ended March 31, 2021 and 2020, our product placements (units recognized as revenue) by device type were as follows:

Three Months Ended March 31, 

2021

2020

Product Placements:

    

  

    

  

MX908

 

53

 

23

Rebel

 

9

 

3

ZipChip Interface

 

4

 

7

Total placements

 

66

 

33

23

Table of Contents

The number of product placements vary considerably from period-to-period due to the type and size of our customers and concentrations among larger government customers as described above. We also have been impacted by laboratory shutdowns related to COVID-19, especially with our ZipChip Interface device. We expect continued fluctuations in our period-to-period number of product placements.

As of March 31, 2021 and 2020, our cumulative product placements consisted of the following number of devices:

Three Months Ended March 31, 

2021

2020

Cumulative Product Placements:

    

  

    

  

MX908

 

1,211

 

850

Rebel

 

55

 

16

ZipChip Interface

 

161

 

138

Cumulative Product Placements

 

1,427

 

1,004

Components of Our Results of Operations

Revenue

Product and Service Revenue

We generate product and service revenue from the sale of our devices and recurring revenue from the sale of consumables and services. Device sales accounted for 73% and 75% of our product and service revenue for the three months ended March 31, 2021 and 2020, respectively. Consumables and service revenue accounted for 27% and 25% of our product and service revenue for the three months ended March 31, 2021 and 2020, respectively.

Our current device offerings include:

Handheld devices—MX908; and
Desktop devices—Rebel and ZipChip Interface.

We sell our devices directly to customers and through distributors. Each of our device sales drives various streams of recurring revenue comprised of consumable product sales and service revenue.

Our consumables consist of:

MX908—accessories and swabs;
Rebel—consumables kit with a microfluidic chip and standards; and
ZipChip Interface—microfluidic chip, reagent and assay kits.

Rebel and ZipChip Interface consumables can only be used with our devices and there are no alternative after-market options that can be used as a substitute. Each chip is used for a defined number of samples (or runs). We recognize revenue from the sale of consumables as the consumable products are shipped.

We also offer our customers extended warranty and service plans. Our extended warranty and service plans are offered for periods beyond the standard one-year warranty that all of our customers receive. These extended warranty and service plans generally have fixed fees and terms ranging from one additional year to four additional years. We recognize revenue from the sale of extended warranty and service plans over the respective coverage period, which approximates the service effort provided by us.

We expect consumables and service revenue to increase in future periods as our installed base grows and we are able to generate recurring sales.

Licenses and contract revenue

License and contract agreements are arrangements whereby we provide engineering services for the development of our technology platform for specific programs or new and expanding applications of our technologies for future

24

Table of Contents

commercial endeavors. Our license and contract agreements are with the U.S. government and commercial entities (who may be contracting with the government). Contracts typically include compensation for labor effort and materials incurred related to the deliverables under the contract. Our license and contract revenue was primarily related to one customer during the three months ended March 31, 2021 and 2020.

During the three months ended March 31, 2021 and 2020, our revenue was comprised of revenue from the following sources:

Three Months Ended March 31, 

2021

2020

(in thousands)

Product and service revenue:

    

  

    

  

Device sales revenue

$

3,911

$

1,988

Consumables and service revenue

 

1,446

 

651

Total product and service revenue

 

5,357

 

2,639

License and contract revenue

 

186

 

1,362

Total revenue

$

5,543

$

4,001

Our product and service revenue is comprised of sales of our handheld and desktop devices and related consumables and service contracts to end-users in the government, pharmaceuticals/biotechnology and academia markets as follows:

Three Months Ended March 31, 

2021

2020

(in thousands)

Product and Service Revenue by Device:

    

  

    

  

Handheld

$

3,240

$

1,540

Desktop

 

2,117

 

1,099

Total product and service revenue

$

5,357

$

2,639

Three Months Ended March 31, 

2021

2020

(in thousands)

Product and Service Revenue by Market:

    

  

    

  

Government

$

3,234

$

1,445

Pharmaceutical/Biotechnology

 

2,100

 

1,183

Academia

 

23

 

11

Total product and service revenue

$

5,357

$

2,639

We sell our products primarily in the United States; however, we are expanding our global sales efforts as we see traction in our products and assess market needs. The majority of our international sales are through a distribution channel.

Cost of Revenue, Gross Profit and Gross Margin

Product cost of revenue primarily consists of costs for raw material parts and associated freight, shipping and handling costs, royalties, contract manufacturer costs, salaries and other personnel costs, overhead and other direct costs related to those sales recognized as product revenue in the period.

Cost of revenue for services primarily consists of salaries and other personnel costs, travel related to services provided, facility costs associated with training, warranties and other costs of servicing equipment on a return-to-factory basis and at customer sites. License and contract cost of revenue primarily consists of salaries and other personnel costs, materials, travel and other direct costs related to the revenue recognized in the period. The license and contract cost of

25

Table of Contents

revenue will vary based upon the type of contract, including whether it is primarily for development services or for both materials and development services.

We expect that our cost of revenue will increase or decrease to the extent that our revenue increases and decreases and depending on how many contracts we have ongoing at any given point in time and the stage of those contracts.

Gross profit is calculated as revenue less cost of revenue. Gross profit margin is gross profit expressed as a percentage of revenue. Our gross profit in future periods will depend on a variety of factors, including: market conditions that may impact our pricing, sales mix among devices, sales mix changes among consumables, excess and obsolete inventories, our cost structure for manufacturing operations relative to volume, and product warranty obligations. Our gross profit in future periods will vary based upon our channel mix and may decrease based upon our distribution channels and the potential to establish original equipment manufacturing channels for certain components of our technology platform which would have a lower gross margin.

We expect that our gross profit margin for product and service will increase over the long term as our sales and production volumes increase and our cost per unit decreases due to efficiencies of scale. We intend to use our design, engineering and manufacturing capabilities to further advance and improve the efficiency of our manufacturing, which we believe will reduce costs and increase our gross margin. We expect that our gross profit margin for license and contract will remain consistent for our contracts that are cost reimbursement contracts.

Operating Expenses

Research and development expenses

Research and development expenses consist primarily of costs incurred for our research activities, product development, hardware and software engineering and consultant services and other costs associated with our technology platform and products, which include:

employee-related expenses, including salaries, related benefits and stock-based compensation expense for employees engaged in research and hardware and software development functions;
the cost of maintaining and improving our product designs, including third party development costs for new products and materials for prototypes;
research materials and supplies; and
facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance.

We believe that our continued investment in research and development is essential to our long-term competitive position and expect these expenses to increase in future periods.

Selling, general and administrative expenses

Selling, general and administrative expenses consist primarily of salaries and other personnel costs, and stock-based compensation for our sales and marketing, finance, legal, human resources and general management, as well as professional services, such as legal, audit and accounting services. We expect selling, general and administrative expenses to increase in future periods as the number of sales, sales application specialists and marketing and administrative personnel grows and we continue to introduce new products, invest in demonstration equipment, broaden our customer base and grow our business. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company.

26

Table of Contents

Other Income (Expense)

Interest expense

Interest expense consists of interest expense associated with outstanding borrowings under our loan and security agreements and the amortization of deferred financing costs and debt discounts associated with such arrangements. In the three months ended March 31, 2021, our interest expense also included our loss on debt extinguishment resulting from the early repayment of debt with proceeds from a new debt facility.

Other income (expense), net

Other income (expense), net consists primarily of the change in fair value of our redeemable convertible preferred stock warrants. We classified warrants for the purchase of shares of our redeemable convertible preferred stock as a liability on our condensed consolidated balance sheets as these warrants were freestanding financial instruments that may have required us to transfer assets upon exercise. The warrant liability was initially recorded at fair value upon the date of issuance of each warrant and was subsequently remeasured to fair value at each reporting date. Changes in the fair value of the warrant liability were recognized as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. On December 22, 2020, immediately prior to the closing of our IPO, the warrants to purchase preferred stock were converted into warrants to purchase common stock, and the fair value of the warrant liability at that time was reclassified to additional paid-in capital. As a result, subsequent to the closing of our IPO, we no longer remeasure the fair value of the warrant liability at each reporting date.

Other income (expense), net also consists of miscellaneous other income and expense unrelated to our core operations.

Provision for Income Taxes

We have not recorded any U.S. federal or state income tax benefits for the net operating losses we have incurred in each year or for the research and development tax credits we generated in the United States, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss carryforwards and tax credits will not be realized. As of December 31, 2020, we had U.S. federal and state net operating loss carryforwards of $59.2 million and $35.9 million, respectively, which may be available to offset future taxable income and begin to expire in 2032 and 2025, respectively, of which $24.8 million of federal net operating losses do not expire. As of December 31, 2020, we also had U.S. federal and state research and development tax credit carryforwards of $4.1 million and $2.3 million, respectively, which may be available to offset future tax liabilities and begin to expire in 2032 and 2029, respectively. We have recorded a full valuation allowance against our net deferred tax assets at each balance sheet date.

27

Table of Contents

Results of Operations

Comparison of the Three Months ended March 31, 2021 and 2020

The following table summarizes our results of operations for the three months ended March 31, 2021 and 2020:

Three Months Ended March 31, 

2021

2020

Change

(in thousands)

Revenue:

    

  

    

  

    

  

Product and service revenue

$

5,357

$

2,639

$

2,718

License and contract revenue

 

186

 

1,362

 

(1,176)

Total revenue

 

5,543

 

4,001

 

1,542

Cost of revenue:

 

  

 

  

 

  

Product and service cost of revenue

 

2,560

 

1,570

 

990

License and contract cost of revenue

 

75

 

333

 

(258)

Total cost of revenue

 

2,635

 

1,903

 

732

Gross profit

 

2,908

 

2,098

 

810

Operating expenses:

 

  

 

  

 

  

Research and development

 

2,965

 

2,156

 

809

Selling, general and administrative

 

5,753

 

2,706

 

3,047

Total operating expenses

 

8,718

 

4,862

 

3,856

Loss from operations

 

(5,810)

 

(2,764)

 

(3,046)

Other income (expense):

 

  

 

  

 

  

Interest expense

 

(376)

 

(241)

 

(135)

Other income (expense), net

 

91

 

39

 

52

Total other expense, net

 

(285)

 

(202)

 

(83)

Net loss

$

(6,095)

$

(2,966)

$

(3,129)

Revenue, Cost of Revenue and Gross Profit

Product and service

    

Three Months Ended March 31,

    

Change

 

2021

2020

Amount

%

(dollars in thousands)

 

Product and service revenue

$

5,357

$

2,639

$

2,718

 

103

%

Product and service cost of revenue

 

2,560

 

1,570

 

990

 

63

%

Gross profit

$

2,797

$

1,069

$

1,728

 

162

%

Gross profit margin

 

52

%  

 

41

%  

 

11

%  

  

Our product and service revenue is comprised of revenue from sales of devices and related consumables and service as follows:

Three Months Ended March 31,

Change

 

    

2021

    

2020

    

Amount

    

%

 

(dollars in thousands)

 

Device sales revenue

$

3,911

$

1,988

$

1,923

 

97

%

Consumables and service revenue

 

1,446

 

651

 

795

 

122

%

Total product and service revenue

$

5,357

$

2,639

$

2,718

 

103

%

Product and service revenue increased by $2.7 million, or 103%, for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. Device sales accounted for 73% and 75% of our product and service revenue for the three months ended March 31, 2021 and 2020, respectively. Consumables and service revenue

28

Table of Contents

accounted for 27% and 25% of our product and service revenue for the three months ended March 31, 2021 and 2020, respectively. The increase in device sales of $1.9 million was primarily due to an increase of $1.4 million in handheld device sales driven by an increase of 30 MX908’s. We also had a $0.5 million increase in device sales related to our desktop products primarily due to a six unit increase in Rebel sales in the three months ended March 31, 2021, partially offset by a decrease in sales of our ZipChip Interfaces. We commercially launched Rebel in the fourth quarter of 2019. Consumables and service revenue increased by $0.8 million primarily due to an increase in service revenue of $0.4 million and an increase of $0.3 million in Rebel kit sales.

Product and service cost of revenue increased by $1.0 million, or 63%, for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. The increase in product and service cost of revenue was primarily related to a $0.7 million increase in materials costs related to volume increases and a $0.2 million increase in personnel related costs as we build out the capacity within operations and service resources.

Product and service gross profit increased by $1.7 million, or 162%, and gross profit margin increased by 11 percentage points for the three months ended March 31, 2021 as compared to the three months ended March 31, 2020, primarily due to MX908 sales volume which leveraged our fixed costs related to our manufacturing facility.

License and contract

Three Months Ended March 31,

Change

 

    

2021

2020

Amount

%

 

(dollars in thousands)

 

License and contract revenue

$

186

$

1,362

$

(1,176)

 

(86)

%

License and contract cost of revenue

 

75

 

333

 

(258)

 

(77)

%

Gross profit

$

111

$

1,029

$

(918)

 

(89)

%

Gross profit margin

 

60

%  

 

76

%  

 

(16)

%  

  

License and contract revenue decreased by $1.2 million, or 86%, for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. The decrease in license and contract revenue was primarily related to decreased activities under our subcontract agreement with a commercial entity that holds a U.S. government prime contract.

License and contract cost of revenue decreased $0.3 million, or 77% for the three months ended March 31, 2021, compared to the three months ended March 31, 2020 due to the decrease in activities under the subcontract agreement.

License and contract gross profit decreased by $0.9 million, or 89%, and gross profit margin decreased by 16 percentage points for the three months ended March 31, 2021 as compared to the three months ended March 31, 2020, primarily due to the mix in contract deliverables during the quarter ended March 31, 2021.

Operating Expenses

Research and development